Estudo de novos modelos experimentais em doença pulmonar alérgica em modelo murino

• Ano de defesa: 2011
• Autor(a) principal: Schmidt, Camila Zanelatto Parreira
• Orientador(a): Pitrez, Paulo Márcio Condessa
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Pontifícia Universidade Católica do Rio Grande do Sul; Porto Alegre
• Palavras-chave em Português: MEDICINA; HIPERSENSIBILIDADE RESPIRATÓRIA; ASMA; EPIDEMIOLOGIA EXPERIMENTAL; EXPERIMENTAÇÃO ANIMAL
• Link de acesso: http://hdl.handle.net/10923/4670

Introduction: Animal models studies of asthma have been criticized because of some limitations. Protocols with features and remote results of human asthma are widely used, mainly because of the need to use adjuvant and intraperitoneal administration of allergens for sensitization. Aims: We have tested alternative protocols using animal models of acute and chronic asthma, with features closer to human disease, using OVA without adjuvant. Methods: Adult female BALB/c mice were used and divided into groups according to sensitization with OVA. The acute model used two doses of OVA subcutaneously (s. c. ) without adjuvant, on days 0 and 7, and after intranasal (i. n. ) challenge for consecutives three days, compared with a standard protocol using three doses of OVA for sensitization. The chronic model also used OVA s. c. for sensitization, adjuvant-free, on days 0 and 14, and after i. n. challenge, 3 times a week, for consecutives eight weeks. Total (TCC) and differential cell counts from bronchoalveolar lavage (BAL) and histopathology of the lungs were performed 24 hours after the last OVA challenge. Results: In the two models of protocols studied, acute and chronic, we have observed similar allergic pulmonary response between the groups. Cell counts and histological analysis of lung tissue showed no significant difference between groups. Conclusion: the use of sensitization with OVA s. c., with no adjuvant, resulted in an expected allergic pulmonary response, with predominant eosinophils. These protocols may be a future option to animal models of asthma closer to the human disease, both in the acute and chronic patterns.